PMID- 25091939
OWN - NLM
STAT- MEDLINE
DCOM- 20151109
LR  - 20220330
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
VI  - 41
IP  - 10
DP  - 2014 Oct
TI  - Transarterial chemoembolization combined with sorafenib for unresectable 
      hepatocellular carcinoma: a systematic review and meta-analysis.
PG  - 6575-82
LID - 10.1007/s11033-014-3541-7 [doi]
AB  - Sorafenib in combination with Transarterial chemoembolization (TACE) is 
      increasingly used in patients with unresectable hepatocellular carcinoma (HCC), 
      but the current evidence is still controversial. The aim of this systematic 
      review was to evaluate the effectiveness and safety of TACE plus sorafenib versus 
      TACE alone for unresectable HCC. We searched PubMed, EMBASE and the Cochrane 
      Library for clinical trials comparing TACE plus sorafenib with TACE alone for 
      unresectable HCC. The study outcomes included overall survival (OS), time to 
      progression (TTP), objective response and adverse events (AEs). Six studies 
      including 1,181 patients were included. Meta-analysis of all studies suggested 
      that the combination therapy group had significant longer OS than TACE group 
      [hazard ratio (HR) = 0.64, 95 % confidence interval (CI) = 0.43-0.97], but the 
      pooled HR of randomized controlled trials (RCTs) failed to achieve statistical 
      significance. For TTP, meta-analysis in both RCTs subgroup and retrospective 
      studies subgroup suggested that combination therapy was superior to TACE group. 
      The combination therapy was also associated with better response to treatment 
      (risk ratio = 1.45, 95 % CI = 1.04-2.02) when both RCTs and retrospective studies 
      were pooled. However, the sorafenib associated AEs were more frequent in the 
      combination therapy group. In conclusion, the combination of TACE and sorafenib 
      is likely to improve OS, TTP and response to treatment when compared with TACE 
      monotherapy. The combination group is also associated with more sorafenib-related 
      AEs.
FAU - Yang, Man
AU  - Yang M
AD  - Department of Digestive Interventional Radiology, Xijing Hospital of Digestive 
      Diseases, Fourth Military Medical University, 127 West Changle Road, Xi'an, 
      710032, China.
FAU - Yuan, Jin-Qiu
AU  - Yuan JQ
FAU - Bai, Ming
AU  - Bai M
FAU - Han, Guo-Hong
AU  - Han GH
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20140805
PL  - Netherlands
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Carcinoma, Hepatocellular/mortality/*pathology/*therapy
MH  - *Chemoembolization, Therapeutic
MH  - Combined Modality Therapy
MH  - Disease Progression
MH  - Humans
MH  - Liver Neoplasms/mortality/*pathology/*therapy
MH  - Neoplasm Staging
MH  - Niacinamide/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Phenylurea Compounds/administration & dosage/adverse effects/*therapeutic use
MH  - Publication Bias
MH  - Sorafenib
MH  - Treatment Outcome
EDAT- 2014/08/06 06:00
MHDA- 2015/11/10 06:00
CRDT- 2014/08/06 06:00
PHST- 2013/06/29 00:00 [received]
PHST- 2014/06/19 00:00 [accepted]
PHST- 2014/08/06 06:00 [entrez]
PHST- 2014/08/06 06:00 [pubmed]
PHST- 2015/11/10 06:00 [medline]
AID - 10.1007/s11033-014-3541-7 [doi]
PST - ppublish
SO  - Mol Biol Rep. 2014 Oct;41(10):6575-82. doi: 10.1007/s11033-014-3541-7. Epub 2014 
      Aug 5.